The Central Nervous System Therapeutics Market dynamics are strongly characterized by rising healthcare expenditure globally, particularly in developed nations. Governments and private health payers are increasing their allocation of resources to accommodate the rising burden of neurological and psychiatric diseases. This increased funding is critical for ensuring patient access to costly, yet often life-altering, innovative CNS therapies, thereby sustaining market growth.

Furthermore, the Central Nervous System Therapeutics Market dynamics are influenced by the expanding orphan drug landscape. Many neurodegenerative and rare neurological disorders qualify for orphan drug designation, which offers regulatory incentives and market exclusivity to pharmaceutical companies. This mechanism encourages investment in drug development for conditions with high unmet needs, leading to the introduction of specialized, high-value treatments that significantly contribute to the overall market valuation.